News
Analysts’ view on the stock has dramatically changed over the past few months. Currently, only 21% of the 29 analysts ...
Sarepta stock sees upgrades and price hikes as analysts reassess Elevidys prospects following a favorable FDA development.
Sarepta Therapeutics (NASDAQ:SRPT) shares dropped sharply premarket on Monday before paring losses as Barclays revised its ...
This regulatory relief, combined with several other compelling catalysts, creates a pathway for the stock to potentially ...
In its own communique issued shortly after the FDA’s, Sarepta elaborated on the situation and confirmed a Roche statement to ...
A 51-year-old man died last month after receiving an experimental treatment from Sarepta, the third death this year tied to ...
Sarepta Therapeutics, Inc. faces setbacks with Elevidys, safety issues, and workforce cuts, raising concerns about its ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback